Carl Dambkowski Sells 18,700 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 18,700 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $77.84, for a total value of $1,455,608.00. Following the transaction, the insider directly owned 212,523 shares of the company’s stock, valued at $16,542,790.32. This trade represents a 8.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Thursday, December 4th, Carl Dambkowski sold 10,900 shares of Apogee Therapeutics stock. The stock was sold at an average price of $75.00, for a total value of $817,500.00.
• On Wednesday, November 5th, Carl Dambkowski sold 10,785 shares of Apogee Therapeutics stock. The shares were sold at an average price of $55.07, for a total value of $593,929.95.

Apogee Therapeutics Trading Up 0.7%

APGE traded up $0.51 during trading on Friday, reaching $77.99. 818,317 shares of the company were exchanged, compared to its average volume of 961,845. Apogee Therapeutics Inc. has a 52 week low of $26.20 and a 52 week high of $80.99. The firm has a 50 day moving average of $70.89 and a 200 day moving average of $51.85. The stock has a market cap of $5.33 billion, a P/E ratio of -17.81 and a beta of 1.41.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.11) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.03. As a group, analysts forecast that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft began coverage on Apogee Therapeutics in a report on Tuesday, December 9th. They issued a “buy” rating and a $103.00 price objective for the company. Craig Hallum reissued a “buy” rating and set a $116.00 price target on shares of Apogee Therapeutics in a report on Wednesday. Stifel Nicolaus set a $133.00 price objective on shares of Apogee Therapeutics in a research note on Tuesday. BTIG Research set a $137.00 price objective on shares of Apogee Therapeutics in a report on Tuesday. Finally, Wall Street Zen cut shares of Apogee Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Apogee Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $104.27.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC grew its holdings in Apogee Therapeutics by 99.2% during the second quarter. Nisa Investment Advisors LLC now owns 769 shares of the company’s stock worth $33,000 after acquiring an additional 383 shares during the period. ANTIPODES PARTNERS Ltd raised its holdings in shares of Apogee Therapeutics by 41.2% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock worth $33,000 after purchasing an additional 246 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Apogee Therapeutics by 18.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,779 shares of the company’s stock worth $77,000 after purchasing an additional 272 shares in the last quarter. Quantbot Technologies LP acquired a new position in Apogee Therapeutics in the third quarter worth approximately $96,000. Finally, BNP Paribas Financial Markets lifted its position in shares of Apogee Therapeutics by 34.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,649 shares of the company’s stock valued at $158,000 after acquiring an additional 941 shares during the last quarter. Institutional investors own 79.04% of the company’s stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.